Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: The key role of early, low-dose flutamide

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 9, 2004, Pages 4716-4720

  Ibáñez, Lourdes ^a   Valls, Carme ^a   Cabré, Sergi ^a   De Zegher, Francis ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; DROSPIRENONE PLUS ETHINYLESTRADIOL; FLUTAMIDE; GLUCOSE; INSULIN; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TESTOSTERONE;

ADIPOSE TISSUE CELL; ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; LIPID COMPOSITION; LIPOLYSIS; LOW DRUG DOSE; OVARIAN VEIN; OVARY BLOOD FLOW; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; VASCULAR RESISTANCE;

ADIPONECTIN; ADOLESCENT; ANDROSTENES; ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEMALE; FLUTAMIDE; HUMANS; HYPERANDROGENISM; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; LIPOLYSIS; METFORMIN; POLYCYSTIC OVARY SYNDROME; PROTEINS;

FALLOPIA;

EID: 4344566243     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0047     Document Type: Article

References (49)

1. Dunaif A, Thomas A 2000 Current concepts in the polycystic ovary syndrome. Annu Rev Med 52:401-419
2. Baumann EE, Rosenfield RL 2002 Polycystic ovary syndrome in adolescence. Endocrinologist 12:333-348
3. Asunción M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale H 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85:2434-2438
4. Kirchengast S, Huber J 2001 Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16:1255-1260
5. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F 2003 Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab 88:2600-2606
6. Ibáñez L, de Zegher F 2003 Flutamide-metformin to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88: 4720-4724
7. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:4649-4654
8. Ibáñez L, de Zegher F 2004 Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 89:1592-1597
9. Ibáñez L, Valls C, Ferrer A, Ong K, Dunger D, de Zegher F 2002 Additive effects of insulin-sensitizing and antiandrogen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia and anovulation. J Clin Endocrinol Metab 87:2870-2874
10. Nestler JE 2002 Should patients with polycystic ovary syndrome be treated with metformin? An enthusiastic endorsement. Hum Reprod 17:1950-1953
11. de Leo V, La Marca A, Petraglia F 2003 Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633-667
12. Costello MF, Eden JA 2003 A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 79:1-13
13. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE 2003 Controversies in endocrinology. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 88:1927-1932
14. Parsey KS, Pong A 2000 An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestagen. Contraception 61:105-111
15. Krattenmacher R 2000 Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62:29-38
16. Azziz R 2003 Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 80:252-254
17. Vrtacnik E, Meden-Vrtovec H 1998 Utero-ovarian arterial blood flow and hormonal profile in patients with polycystic ovary syndrome. Hum Reprod 13:815-821
18. Battaglia C, Artini PG, Genazzani AD, Sgherzi MR, Salvatori M, Giulini S, Volpe A 1995 Color Doppler analysis in lean and obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol 7:342-346
19. Ajossa S, Guerriero S, Paoletti AM, Orrù M, Melis GB 2002 The antiandrogenic effect of frutamide improves uterine perfusion in women with polycystic ovary syndrome. Fertil Steril 77:1136-1140
20. Vidal-Puig A, Moller DE 1997 Insulin resistance: classification, prevalence, clinical manifestations, and diagnosis. In: Azziz R, Nestler JE, Dewailly D, eds. Androgen excess disorders in women. Philadelphia: Lippincott-Raven Publishers; 227-236
21. Ibáñez L, Potau N, Zampolli M, Riqué S, Saenger P, Carrascosa A 1997 Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 82:2283-2288
22. Ferriman D, Gallwey JD 1961 Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440-1447
23. Ibáñez L, Potau N, Zampolli M, Prat N, Gussinyé M, Saenger P, Vicens-Calvet E, Carrascosa A 1994 Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab 79:1778-1784
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 1997 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
25. New MI, Lorenzen F, Lerner AJ, Kohn B, Oberfield SE, Pollack MS, Dupont B, Stoner E, Levy DJ, Pang S, Levine LS 1983 Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 56:320-325
26. Sakkal-Alkaddour H, Zhang L, Yang X, Chang YT, Kappy M, Slover RS 1996 Studies of 3β-hydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated Δ5-steroid levels. J Clin Endocrinol Metab 81:3961-3965
27. Adams J, Polson DW, Abdulwahid N, Morris DV, Franks S, Mason HD, Tucker M, Price J 1985 Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 2:1375-1379
28. Ibáñez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger D 2003 Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from pre-puberty to post-menarche. Clin Endocrinol (Oxf) 58:372-379
29. Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A 1998 Body mass index, waist girth, and waist-to-hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. Am J Clin Nutr 67:44-49
30. Kiebzak GM, Leamy LJ, Pierson LM, Nord RH, Zhang ZY 2000 Measurement precision of body composition variables using the Lunar DPX-L densitometer. J Clin Densitom 3:35-41
31. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM 2003 Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 13:674-682
32. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy II PF, Fitzpatrick LA 2003 Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:2562-2568
33. Elting MW, Korsen TJM, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellicus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 16:556-560
34. Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J 2000 Increased risk of non-insulin dependent diabetes mellirus arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 15:785-789
35. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ 1998 The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83:2699-2705
36. Ibáñez L, Potau N, Marcos MV, de Zegher F 2000 Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in non-obese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85: 3251-3255
37. de Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G 1998 Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:99-102
38. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F 2000 Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 85:3526-3530
39. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaterani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y 2002 Androgens decrease plasma adiponectin, and insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734-2741
40. Yang L, Wang L, Lin HK, Kan PY, Xie S, Tsai MY, Wang PH, Chen YT, Chang C 2003 Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem Biophys Res Commun 305:462-469
41. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R 2003 Adiponectin gene expression and secretion is inhibited by interleukin-6 and sT3-L1 adipocytes. Biochem Biophys Res Commun 301:1045-1050
42. Fernández-Real JM, Broch M, Vendrell J, Richart C, Ricart W 2000 Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85:1334-1339
43. Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE, Shulman G, Caprio S 2003 Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab 88: 2014-2018
44. Culig Z 2003 Role of the androgen receptor axis in prostate cancer. Urology 62(Suppl 5A):21-26
45. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE 2001 The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953
46. Woodhouse LJ, Gupta N, Bhasin M, Singh AB, Ross R, Phillips J, Bhasin S 2004 Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J Clin Endocrinol Metab 89:718-726
47. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-E1181
48. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N 2000 Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 85:2839-2853
49. Anderson LA, McTernan PG, Harte AL, Barnett AH, Kumar S 2002 The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. Diabetes Obes Metab 4:209-213